Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Mission Wealth Management LP

Mission Wealth Management LP lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.7% during the 4th quarter, Holdings Channel reports. The fund owned 57,246 shares of the medical research company’s stock after selling 971 shares during the quarter. Mission Wealth Management LP’s holdings in Edwards Lifesciences were worth $4,365,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of EW. Sumitomo Life Insurance Co. raised its holdings in shares of Edwards Lifesciences by 3.4% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 25,516 shares of the medical research company’s stock worth $1,768,000 after acquiring an additional 833 shares during the period. Commonwealth Equity Services LLC raised its holdings in Edwards Lifesciences by 7.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 163,984 shares of the medical research company’s stock valued at $11,361,000 after buying an additional 11,117 shares during the period. Suncoast Equity Management raised its holdings in Edwards Lifesciences by 3.6% in the 3rd quarter. Suncoast Equity Management now owns 8,450 shares of the medical research company’s stock valued at $585,000 after buying an additional 295 shares during the period. Litman Gregory Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at about $8,691,000. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in Edwards Lifesciences by 2.6% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 39,392 shares of the medical research company’s stock valued at $2,729,000 after buying an additional 1,011 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 in the last three months. Company insiders own 1.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on EW shares. Royal Bank of Canada boosted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Evercore ISI lowered their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday. Morgan Stanley raised their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Citigroup raised their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Finally, OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Edwards Lifesciences Stock Down 1.5 %

Shares of Edwards Lifesciences stock traded down $1.28 during trading on Tuesday, hitting $84.67. 2,881,572 shares of the stock traded hands, compared to its average volume of 3,828,306. The stock has a market cap of $50.97 billion, a P/E ratio of 37.05, a PEG ratio of 4.28 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a fifty day moving average price of $90.27 and a two-hundred day moving average price of $79.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.